Germany – Pharmaceutical products – Open-House-Originale-Rabattverträge 2026-07 Fluticason/Vilanterol (Wirkstoffkombination)
Description
The participating funds aim to conclude discount contracts pursuant to § 130a para. 8 SGB V with all suitable pharmaceutical companies for the active substance combination Fluticasone/Vilanterol. The contract is concluded within the framework of the Open House Original procedure of the participating funds: Individual negotiations on contract contents are not conducted, uniform conditions apply. The participating health insurers do not guarantee exclusivity to individual contracting partners. The contract period is a maximum of 24 months, beginning on 01.10.2026. The contract ends at the latest on 30.09.2028, regardless of the date of the contract conclusion. In the event of patent expiry/loss of market exclusivity before the above end date, the contract ends automatically at the end of the month of patent expiry/loss of market exclusivity. Joining this Open House Original procedure is possible at any time during the contract period. All further information can be found in the participation and contract documents.
CPV codes
Documents & submission
Contains data from Tenders Electronic Daily (TED), © European Union, ted.europa.eu — CC BY 4.0.
Related tenders
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Glycopyrronium + Indacaterol, ATC R03AL12 für die Zeit 01.01.2027 - 31.12.2028
DAK-GesundheitGermanyPharmaceutical productsDeadline in 719 daysPublished on Nov 16, 2026
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Mometason (ausschl. in der Dafo. Lösung), ATC D07AC13 f. d. Z. 01.01.2027-31.12.2028 (zzgl. V.-Option 1x12 M)
DAK-GesundheitGermanyPharmaceutical productsDeadline in 1,084 daysPublished on Nov 16, 2026
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Pamidronsäure, ATC M05BA03 für die Zeit 01.01.2027 - 31.12.2028 (zzgl. V.-Option 1x12 Monate)
DAK-GesundheitGermanyPharmaceutical productsDeadline in 1,084 daysPublished on Nov 16, 2026
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Morphin (ausschl. in der Dafo. FTA + HKP + SMT), ATC N02AA01 f. d. Z. 01.01.27-31.12.28, zzgl V.-Option 1x12M
DAK-GesundheitGermanyPharmaceutical productsDeadline in 1,084 daysPublished on Nov 16, 2026